Investigational product supply is one of the most underestimated risks in early clinical development. The risk hides in manufacturing lead times, release testing, short expiry dating, country-specific labeling, import requirements, depot setup, resupply settings and temperature control. Sponsors avoid surprises by planning supply early, tying forecasts to enrollment scenarios and giving one person clear ownership.
Where does clinical supply go wrong?
Manufacturing or release testing takes longer than planned.
Limited stability data mean short expiry dates, forcing relabeling or resupply mid-study.
Label text and approvals differ by country.
Import permits and depot setup take longer than expected.
Randomization and supply system settings trigger shipments too late or too early.
Temperature excursions make product unusable.
Overage is cut to save money, leaving no buffer.
Dose changes after escalation require strengths or kits that don't exist yet.
What should a clinical supply plan include?
A demand forecast built on enrollment scenarios, not a single number. Packaging and labeling design that protects blinding. A distribution network of depots and couriers. A resupply strategy, including the thresholds in the randomization system. Expiry management. Procedures for temperature excursions, returns and destruction. Reconciliation. And comparator or rescue medication sourcing where needed.
How does supply connect to the protocol?
Closely. Dose levels, titration schemes, visit schedules and blinding all determine kit design. A protocol amendment that adds a dose level or changes a visit schedule can require new kits, new labels and new forecasts. Involve your supply lead in protocol design and in every amendment discussion.
Who should own clinical supply?
Usually a CMC or supply chain lead, working closely with clinical operations, the randomization vendor, depots and the CRO. In small companies, supply decisions are sometimes made by manufacturing colleagues without clinical scenario input. Bring both perspectives into the same governance meeting so enrollment changes and supply realities are seen together.
Supply planning also benefits from a simple scenario exercise before first patient in. Ask what happens to drug availability if enrollment runs twice as fast as planned, or if the study extends six months beyond its planned end. If either scenario breaks the supply plan, adjust the forecast, the overage or the manufacturing schedule now.
What are the common small-sponsor pitfalls?
Relying on a single batch. Minimizing overage to conserve budget or drug substance. Not watching expiry dates against the realistic timeline, rather than the planned one. And assuming the CRO is managing supply when its scope doesn't include it.
Which metrics should you watch?
Stock levels at sites and depots, days of supply remaining, temperature excursions and their resolution, and the expiry horizon compared with the projected study end. These belong on the same dashboard as enrollment, because they are two sides of the same forecast.
Keep reading: Who Owns the Seams Between Your Vendors?
